Reference
1. Chu JJ, Devall AJ, Beeson LE, Hardy P, Cheed V, Sun Y, et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. Lancet 2020 Sep 12;396(10253):770-8.10.1016/S0140-6736(20)31788-8
2. Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medical abortion in the late first trimester: a systematic review. Contraception 2019 Feb;99(2):77-86.10.1016/j.contraception.2018.11.002
3. Wake DT, Ilbawi N, Dunnenberger HM, Hulick PJ. Pharmacogenomics: Prescribing Precisely. The Medical clinics of North America 2019 Nov;103(6):977-90.10.1016/j.mcna.2019.07.002
4. Woodland C, Koren G, Ito S. From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example. Journal of clinical pharmacology 2003 Jul;43(7):743-50
5. Haslam IS, Jones K, Coleman T, Simmons NL. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochemical pharmacology 2008 Oct 1;76(7):850-61.10.1016/j.bcp.2008.07.020
6. Tan Y, Cao K, Ren G, Qin Z, Zhao D, Li N, et al. Effects of the ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of afatinib in healthy Chinese volunteers. Xenobiotica; the fate of foreign compounds in biological systems 2020 Feb;50(2):237-43.10.1080/00498254.2019.1610585
7. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003 Jul;4(4):397-410.10.1517/phgs.4.4.397.22747
8. Jang GR, Wrighton SA, Benet LZ. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochemical pharmacology 1996 Sep 13;52(5):753-61.10.1016/0006-2952(96)00357-7
9. Hamadeh IS, Zhang Q, Steuerwald N, Hamilton A, Druhan LJ, McSwain M, et al. Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Apr;25(4):656-63.10.1016/j.bbmt.2018.12.766
10. Zhao GX, Zhang Z, Cai WK, Shen ML, Wang P, He GH. Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis. Epilepsy research 2021 Jul;173:106615.10.1016/j.eplepsyres.2021.106615
11. Saiz-Rodriguez M, Almenara S, Navares-Gomez M, Ochoa D, Roman M, Zubiaur P, et al. Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. Biomedicines 2020 Apr 22;8(4).10.3390/biomedicines8040094
12. Dong ZL, Li H, Chen QX, Hu Y, Wu SJ, Tang LY, et al. Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population. Journal of clinical pharmacy and therapeutics 2012 Apr;37(2):153-6.10.1111/j.1365-2710.2011.01268.x
13. Su Q, Liu Q, Liu J, Fu L, Liu T, Liang J, et al. Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms. Bioengineered 2021 Dec;12(2):11700-8.10.1080/21655979.2021.2003930
14. Wu WN, McKown LA, Moyer MD, Johannsen TB, Takacs AR. In vitro metabolism of mifepristone (RU-486) in rat, monkey and human hepatic S9 fractions: identification of three new mifepristone metabolites. Xenobiotica; the fate of foreign compounds in biological systems 1999 Nov;29(11):1089-100.10.1080/004982599237976
15. Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lahteenmaki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. Journal of steroid biochemistry 1987 Feb;26(2):279-84.10.1016/0022-4731(87)90083-5
16. Tang C, Bi HC, Zhong GP, Chen X, Huang ZY, Huang M. Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study. Biomedical chromatography : BMC 2009 Jan;23(1):71-80.10.1002/bmc.1086
17. Costescu D, Guilbert E, Bernardin J, Black A, Dunn S, Fitzsimmons B, et al. Medical Abortion. Journal of obstetrics and gynaecology Canada : JOGC = Journal d’obstetrique et gynecologie du Canada : JOGC 2016 Apr;38(4):366-89.10.1016/j.jogc.2016.01.002
18. Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA, et al. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstetrics and gynecology 2007 Apr;109(4):885-94.10.1097/01.AOG.0000258298.35143.d2
19. Wang N, Zhao H, Han W, He B, Zhang S, Wang J. Association of the G2014G genotype in estrogen receptor 1 gene with failure of the mifepristone-induced termination of early pregnancy. The Tohoku journal of experimental medicine 2010 Jan;220(1):77-82.10.1620/tjem.220.77
20. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annual review of pharmacology and toxicology 2003;43:285-307.10.1146/annurev.pharmtox.43.100901.140233
21. Wang D, Sadee W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). The AAPS journal 2006 Aug 18;8(3):E515-20.10.1208/aapsj080361
22. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenetics and genomics 2005 Oct;15(10):693-704
23. Geers LM, Pozhidaev IV, Ivanova SA, Freidin MB, Schmidt AF, Cohen D, et al. Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. British journal of clinical pharmacology 2020 Sep;86(9):1827-35.10.1111/bcp.14288
24. Gusella M, Pasini F, Caruso D, Barile C, Modena Y, Fraccon AP, et al. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms. Cancer chemotherapy and pharmacology 2019 Mar;83(3):493-500.10.1007/s00280-018-3751-0
25. Parvin MN, Aziz MA, Rabbi SNI, Al-Mamun MMA, Hanif M, Islam MS, et al. Assessment of the Link of ABCB1 and NR3C1 gene polymorphisms with the prednisolone resistance in pediatric nephrotic syndrome patients of Bangladesh: A genotype and haplotype approach. Journal of advanced research 2021 Nov;33:141-51.10.1016/j.jare.2021.02.001
26. Canaparo R, Finnstrom N, Serpe L, Nordmark A, Muntoni E, Eandi M, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clinical and experimental pharmacology & physiology 2007 Nov;34(11):1138-44.10.1111/j.1440-1681.2007.04691.x
27. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clinical pharmacokinetics 1994 Feb;26(2):144-60.10.2165/00003088-199426020-00007
28. Sumantran VN, Mishra P, Bera R, Sudhakar N. Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma. Pharmaceutics 2016 Feb 17;8(1).10.3390/pharmaceutics8010004
29. Zhou Q, Yu X, Shu C, Cai Y, Gong W, Wang X, et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. Journal of human genetics 2011 Jun;56(6):415-22.10.1038/jhg.2011.30
30. Chen B, Zhang XD, Wen J, Zhang B, Chen D, Wang S, et al. Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism. Chemical research in toxicology 2020 Jan 21;33(1):172-80.10.1021/acs.chemrestox.9b00186
31. Liu J, Chen Z, Chen H, Hou Y, Lu W, He J, et al. Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients. International journal of molecular sciences 2017 Mar 13;18(3).10.3390/ijms18030603
32. Park JW, Kim KA, Kim JM, Park IH, Park JY. Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans. Frontiers in pharmacology 2021;12:736317.10.3389/fphar.2021.736317
33. Han JM, Yee J, Chung JE, Lee KE, Park K, Gwak HS. Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects. Molecular genetics & genomic medicine 2020 May;8(5):e1201.10.1002/mgg3.1201
34. Huang Y, Wen G, Lu Y, Wen J, Ji Y, Xing X, et al. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation. International journal of clinical pharmacology and therapeutics 2017 Feb;55(2):109-18.10.5414/CP202559
35. Leminen R, Ranta S, von Hertzen H, Oehler J, Heikinheimo O. Pharmacokinetics of 10 mg of mifepristone. Contraception 2003 Dec;68(6):427-9.10.1016/s0010-7824(03)00181-1